Clinical trials: Head and Neck Squamous Cell Carcinomas
Squamous Cell Carcinoma, Laryngeal Cancer
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
The purpose of this prospective, multi-institutional, observational cohort study is to determine if an initial surgical approach leads to better function and quality of life than primary chemoradiation in a subset of patients…
- Trial name
- NCT01089803
- Where
- United States
- Volunteers
- 279 people
- Sponsor
- University of Minnesota
Head and Neck Squamous Cell Carcinoma
Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
This study is a prospective, open-label, single-arm study. The trial will be divided into 3 phases: screening/baseline, treatment and follow-up.
- Trial name
- NCT05351762
- Testing
- Nimotuzumab Combined With Neoadjuvant Chemotherapy
- Volunteers
- 55 people
- Sponsor
- Xijing Hospital
Recurrent Head and Neck Squamous Cell Carcinoma
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Prospective, open-label, randomized controlled phase III trail that aims to investigate whether Re-Radiochemotherapy (Re-RCT) and sequential immunotherapy with pembrolizumab improves overall survival compared to the standard…
- Trial name
- RePaIr-HN (NCT07026474)
- Testing
- radiotherapy, Cisplatin, Pembrolizumab
- Where
- 24 sites in Germany, Switzerland
- Volunteers
- 214 people
- Sponsor
- Universität des Saarlandes
Oral Squamous Cell Carcinoma
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
TPF is still recommended as the preferred induction chemotherapy regimen for nonsurgical treatment of patients with LA HNSCC. Based on the KEYNOTE-048 study, all major guidelines recommend PD-1 monotherapy or PD-1 combined with…
- Trial name
- NCT05862168
- Testing
- Tislelizumab, Albumin paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Weijia Fang, MD
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00387335
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC…
- Trial name
- AFAN (NCT06648096)
- Testing
- Afatinib
- Where
- 2 sites in Germany, Spain
- Volunteers
- 25 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Esophageal Squamous Cell Carcinoma (ESCC)
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease.
- Trial name
- Keystone006 (NCT07721103)
- Testing
- Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
This study compares the efficacy of neoadjuvant low-dose radiotherapy plus targeted-immunotherapy versus targeted-immunotherapy alone in resectable HNSCC patients.
- Trial name
- NCT06804850
- Testing
- Tislelizumab, Afatinib, Low dose radiotherapy
- Sponsor
- West China Hospital
Squamous Cell Carcinoma of the Head and Neck, Oral Mucositis
Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.
This study is a Phase 2, double-blind, randomized controlled trial evaluating the safety and efficacy of TV5M01 (a 5% green tea and 0.1% morphine gel) compared to triple mixture (0.19% lidocaine, 0.29% nystatin, and 5.50%…
- Trial name
- TEMOR (NCT06875791)
- Testing
- Green Tea Extract with Morphine, Active Comparator: Triple Mixture Oral Rinse for Radiation-Induced Mucositis
- Where
- Colombia
- Volunteers
- 40 people
- Sponsor
- Fundacion Clinica Valle del Lili
Squamous Cell Carcinoma, Oropharynx Cancer
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease
- Conditions
- Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
- Trial name
- NCT05535023
- Testing
- SAR444245, Cemiplimab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Oral Complications of Radiation Therapy
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue, prevent or lessen mouth dryness, and may help patients live more…
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00057785
- Testing
- cisplatin, fluorouracil, Intensity modulated radiation therapy
- Where
- 17 sites in United States
- Volunteers
- 68 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Squamous Cell Cancer
Intensive Nutrition Counselling in Patients With Head and Neck Cancer
The purpose of this study is to assess the effect of a pre-planned patient-adjusted intensive nutritional counselling given by a dietitian several times during (chemo)radiotherapy vs.
- Trial name
- NCT02159508
- Testing
- Nutritional counselling
- Where
- Finland
- Volunteers
- 65 people
- Sponsor
- Helsinki University Central Hospital
Neoplasms, Head and Neck
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell…
- Trial name
- INDUCE-3 (NCT04128696)
- Testing
- feladilimab, Pembrolizumab
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 315 people
- Sponsor
- GlaxoSmithKline
Esophageal Squamous Cell Carcinoma (ESCC)
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
This study includes patients with resectable esophageal squamous cell carcinoma who will undergo local radiotherapy (PTV: 1.5Gy Bid, for 5 days), followed by neoadjuvant treatment with Serplulimab combined with cisplatin and…
- Trial name
- NCT07403435
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Head and Neck Squamous Cell Carcinomas, Solid Tumor
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerance, pharmacokinetic characteristics and preliminary effectiveness of BL-B16D1 in recurrent…
- Trial name
- NCT06469008
- Testing
- BL-B16D1
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma, Pathological Complete Response
Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features
This multicenter, retrospective cohort study reviews the medical records and CT scans of adults with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunotherapy plus chemotherapy before surgery at three…
- Trial name
- pCR-ESCC (NCT07181850)
- Testing
- Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Nanjing Medical University
Head and Neck Cancer
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00601913
- Testing
- erlotinib hydrochloride, protein analysis, western blotting
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Squamous Cell Carcinoma of the Head and Neck
Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
The investigators will collect plasma samples at baseline, during treatment, and at progression.
- Trial name
- NCT02139020
- Testing
- Plasma samples
- Where
- 5 sites in Belgium
- Volunteers
- 400 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
This randomized phase Ib trial studies standard-dose or high-dose erlotinib hydrochloride before surgery in treating patients with head and neck cancer.
- Conditions
- Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
- Trial name
- NCT00954226
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center